Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any familial atrial fibrillation in which the cause of the disease is a mutation in the NUP155 gene.
Features include always present findings: Atrial fibrillation; and common findings: Atrial flutter, Sudden cardiac death, and Supraventricular tachycardia. 5 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Heart and blood vessels | 5 | Left atrial enlargement, Atrial fibrillation, Atrial flutter |
NUP155 encodes nucleoporin 155 (1,391 aa). Essential component of nuclear pore complex. Could be essessential for embryogenesis. Nucleoporins may be involved both in binding and translocating proteins during nucleocytoplasmic transport Highest expression in Testis (56.0 TPM) and Cells EBV-transformed lymphocytes (20.8 TPM).
Atrial fibrillation, familial, 15 is associated with mutations in the NUP155 gene on chromosome 5.
NUP155 is classified as a druggable target (Transporter category) with score 0.0.
Genetic testing for NUP155 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for atrial fibrillation, familial, 15 has been reported in the published literature.
Phenotype severity distribution: 1 always present feature, 3 common features.
No clinical trials have been registered for atrial fibrillation, familial, 15.
277 publications have been identified in PubMed for atrial fibrillation, familial, 15. Research spans Epidemiology / Natural History (38%), Clinical Trial Publication (22%), and Review / Meta-Analysis (16%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 94 | 38% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 6:52 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Clinical study results
54 |
22% |
Research summaries | 39 | 16% |
Testing and diagnosis research | 35 | 14% |
Laboratory research | 20 | 8% |
Patient case studies | 3 | 1% |
New treatment approaches | 2 | 1% |
Other research | 1 | 0% |
Okada M (2026). [PMID: 41669962](https://pubmed.ncbi.nlm.nih.gov/41669962/). *J Am Heart Assoc*. [Epidemiology / Natural History]
Nakasone K (2026). [PMID: 41359233](https://pubmed.ncbi.nlm.nih.gov/41359233/). *J Interv Card Electrophysiol*. [Clinical Trial Publication]
Pengo V (2026). [PMID: 41649510](https://pubmed.ncbi.nlm.nih.gov/41649510/). *Handb Exp Pharmacol*. [Review / Meta-Analysis]
Sánchez-Gómez JM (2026). [PMID: 40736426](https://pubmed.ncbi.nlm.nih.gov/40736426/). *Heart Rhythm*. [Epidemiology / Natural History]
Chen J (2026). [PMID: 41559665](https://pubmed.ncbi.nlm.nih.gov/41559665/). *BMC Med*. [Epidemiology / Natural History]
Park H (2026). [PMID: 41352445](https://pubmed.ncbi.nlm.nih.gov/41352445/). *Heart Rhythm*. [Epidemiology / Natural History]
Chen J (2026). [PMID: 40300736](https://pubmed.ncbi.nlm.nih.gov/40300736/). *Heart Rhythm*. [Diagnostic / Biomarker]
Genovese D (2026). [PMID: 41711708](https://pubmed.ncbi.nlm.nih.gov/41711708/). *ESC Heart Fail*. [Clinical Trial Publication]
Mendonça GG (2026). [PMID: 41620299](https://pubmed.ncbi.nlm.nih.gov/41620299/). *Heart Lung Circ*. [Review / Meta-Analysis]
Hu X (2026). [PMID: 40221109](https://pubmed.ncbi.nlm.nih.gov/40221109/). *Heart Rhythm*. [Review / Meta-Analysis]